FIELD: medicine.
SUBSTANCE: suitable for transdermal introduction of rotigotine [(-)-5,6,7,8-tetrahydro-6[propyl[2(2-thienyl)ethyl]amino]-1naphthol] in an organism, the polymeric matrix contains polymer forming it which is supersaturated with rotigotine in the form of the free base, thus not dissolved in a polymer forming a matrix the part of rotigotine is dispersed in it in the form of amorphous particles with average diameter of 30 microns maximum, and hydrotropic solubilisers, inhibitors of crystallisation and dispersants are absent in the matrix. The device of the flat form for transdermal introduction of rotigotine in an organism, containing specified above a rotigotine supersaturated polymeric matrix is described also, it is preferable on a silicon basis, and an impenetrable for rotigotine back layer.
EFFECT: matrix allows to provide therapeutically comprehensible rate of penetration of rotigotine from it through a skin.
14 cl, 7 dwg, 5 ex
